Inventor · disambiguated record
Ede Marvanyos
Also filed as: MARVANYOS EDE · MARVANYOS EDE LASZLO · MARVNYOS EDE
17 granted patents·3 pending applications·209 citations·filing 1983–2015
94Inventor score
Files withCYTRX CORP8BIOREX KUTATO FEJLESZTOE KFT3CHINOIN GYOGYSZER ES VEGYESZET3BIOREX KUTATO ES FEJLESZOERT1BIOREX KUTATO FEJLESZTOE RT1
Top patents by PatentIndex Score
20 records- 0193US7691849B2Carboxamidine derivatives and their use in the treatment of vascular diseasesCYTRX CORP·Filed 2007·Granted Apr 6, 2010·14 cites·27 claims
- 0290US7550457B2Pharmaceutically effective compoundsCYTRX CORP·Filed 2007·Granted Jun 23, 2009·13 cites·19 claims
- 0387US10023566B2Dasatinib saltsEGYT GYOGYSZERVEGYESZETI GYAR·Filed 2015·Granted Jul 17, 2018·16 cites·21 claims
- 0485US7148239B2Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereofCYTRX CORP·Filed 2003·Granted Dec 12, 2006·23 cites·34 claims
- 0584US6649628B1N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistanceBIOREX KUTATO FEJLESZTOE KFT·Filed 2000·Granted Nov 18, 2003·32 cites·10 claims
- 0683US7384936B2Carboxamidine derivatives and their use in the treatment of vascular diseasesCYTRX CORP·Filed 2003·Granted Jun 10, 2008·14 cites·10 claims
- 0782US7361655B2Pharmaceutically effective compoundsCYTRX CORP·Filed 2004·Granted Apr 22, 2008·13 cites·11 claims
- 0880US7745465B2Method of enhancing cellular production of molecular chaperone, hydroxylamine derivatives useful for enhancing the chaperone production and the preparation thereofCYTRX CORP·Filed 2003·Granted Jun 29, 2010·13 cites·11 claims
- 0976US2009253690A1Pharmaceutically effective compoundsCYTRX CORP·Filed 2009·Application pending·0 cites
- 1072US6653326B1Hydroxylamine derivatives useful for enhancing the molecular chaperon production and the preparation thereofBIOREX RES & DEV CO·Filed 1996·Granted Nov 25, 2003·31 cites·31 claims
- 1157US4599428AProcess for the preparation of 5(6)-thio substituted benzimidazolesCHINOIN GYOGYSZER ES VEGYESZET·Filed 1984·Granted Jul 8, 1986·4 cites·11 claims
- 1255US4709081AProcess for the preparation of diphenyl ether derivativesCHINOIN GYOGYSZER ES VEGYESZET·Filed 1985·Granted Nov 24, 1987·5 cites·11 claims
- 1350US2010267711A1Method of enhancing cellular production of molecular chaperone, hydroxylamine derivatives useful for enhancing the chaperone production and the preparation thereofCYTRX CORP·Filed 2010·Application pending·0 cites
- 1448US6384029B1Optically active pyridyl-4h-1,2,4-oxdadiazine derivative and its use in the treatment of vascular diseasesBIOREX KUTATO FEJLESZTOE RT·Filed 1999·Granted May 7, 2002·13 cites·13 claims
- 1545US5919796AHydroximic acid derivatives, pharmaceutical compositions containing them, and processes for preparing the sameBIOREX KUTATO FEJLESZTOE KFT·Filed 1995·Granted Jul 6, 1999·8 cites·21 claims
- 1639US4473697AProduction of thiocyanato benzimidazolesCHINOIN GYOGYSZER ES VEGYESZET·Filed 1983·Granted Sep 25, 1984·1 cites·10 claims
- 1736US6143741APharmaceutical products for curing and preventing illnesses connected with the malfunction of vascular endothelial cellsBIOREX KUTATO ES FEJLESZOERT·Filed 1997·Granted Nov 7, 2000·7 cites·15 claims
- 1836US2001051630A1Use of hydroxylamine derivatives, and method and preparations for increasing the tolerance of field crops against weather stressesFiled 2001·Application pending·0 cites
- 1930US6002002AAnti-ischaemic hydroxylamine derivatives and pharmaceutical compositionsBIOREX RESEARCH & DEV CO·Filed 1996·Granted Dec 14, 1999·2 cites·8 claims
- 2029US6180787B1Process for preparing o-(3-amino-2-hydroxy-propyl)-hydroxymic acid halidesBIOREX KUTATO FEJLESZTOE KFT·Filed 1997·Granted Jan 30, 2001·0 cites·2 claims
Join the waitlist — get patent alerts
Get an alert when Ede Marvanyos files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →